Zolimomab aritox
Zolimomab aritox is a mouse monoclonal antibody which has been investigated for the treatment of systemic lupus erythematosus[1] and graft-versus-host disease,[2] but the studies failed to show positive effects of the drug.
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Mouse |
Target | CD5 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
KEGG | |
|
It is an anti-CD5 antibody which is linked to the A chain of the ricin protein (which is reflected by the aritox in the drug's name).[3]
See also
References
- Stafford, FJ; Fleisher, TA; Lee, G; Brown, M; Strand, V; Austin Ha, 3rd; Balow, JE; Klippel, JH (1994). "A pilot study of anti-CD5 ricin a chain immunoconjugate in systemic lupus erythematosus". The Journal of Rheumatology. 21 (11): 2068–70. PMID 7532717.
- Przepiorka, D; Lemaistre, CF; Huh, YO; Luna, M; Saria, EA; Brown, CT; Champlin, RE (1994). "Evaluation of anti-CD5 ricin a chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation". Therapeutic immunology. 1 (2): 77–82. PMID 7584486.
- WHO Drug Information
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.